Clinical Trials Logo

Clinical Trial Summary

Patients with acute ST-segment elevation myocardial infarction and thrombolysis indications, will be given the recombinant human prourokinase for thrombolysis treatment, and in accordance with the guidelines, will be treated with coronary angiography examination 3 to 24 hours after thrombolysis. The study will explore the best time for interventional therapy combined with thrombolysis.


Clinical Trial Description

The noninferiority multicenter, prospective, randomized, controlled study of urokinase of restructuring the original design evaluation (rhPro - UK) at different times after thrombolysis combined with percutaneous coronary intervention(PCI)therapy of acute ST segment elevation myocardial infarction.Patients with acute ST segment elevation myocardial infarction and thrombolysis indications, will be given the recombinant human prourokinase for thrombolysis treatment, and in accordance with the guidelines, will be treated with coronary angiography examination 3 to 24 hours after thrombolysis. The study will explore the best time for interventional therapy combined with thrombolysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03137212
Study type Interventional
Source Second Hospital of Jilin University
Contact Bin Liu, Doctor
Phone 043188796598
Email liubin3333@vip.sina.com
Status Recruiting
Phase N/A
Start date April 17, 2017
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02914795 - Platelet Function in Resuscitated Patients
Recruiting NCT00697021 - Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance Phase 3
Completed NCT05949515 - Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility
Completed NCT02828683 - Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study N/A
Completed NCT01986803 - ABSORB STEMI: the TROFI II Study N/A
Active, not recruiting NCT01878344 - Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention Phase 3
Withdrawn NCT02048085 - Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis Phase 4
Completed NCT04463251 - Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction Phase 2
Active, not recruiting NCT02943954 - FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction N/A
Completed NCT02298088 - Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis Phase 3
Active, not recruiting NCT02067091 - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct Phase 3
Completed NCT01787110 - An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction Phase 3
Not yet recruiting NCT05802667 - A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction
Completed NCT04730778 - Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients